Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Researchers found a new procedure to prevent a common diabetic eye disease. 1. Many people who have diabetes also get diabetic macular edema, said Caesar Luo, MD, a retinal specialist. 2. Typical ...

Regeneron Pharmaceuticals Inc REGN announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

New Delhi: Ophthalmologists across India are urging the central government to include advanced treatments for diabetic retinopathy under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), the ...